Vertical Sleeve Gastrectomy Lowers SGLT2/Slc5a2 Expression in the Mouse Kidney

被引:2
|
作者
Akalestou, Elina [1 ]
Lopez-Noriega, Livia [1 ]
Tough, Iain R. [2 ]
Hu, Ming [1 ]
Leclerc, Isabelle [1 ,3 ]
Cox, Helen M. [2 ]
Rutter, Guy A. [1 ,3 ,4 ]
机构
[1] Imperial Coll London, Div Diabet Endocrinol & Metab, Sect Cell Biol & Funct Genom, London, England
[2] Wolfson Ctr Age Related Dis, London, England
[3] Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada
[4] Nanyang Technol Univ, Lee Kong Chian Imperial Med Sch, Singapore, Singapore
基金
英国惠康基金; 欧盟地平线“2020”; 英国生物技术与生命科学研究理事会; 英国医学研究理事会;
关键词
Y GASTRIC BYPASS; IMPROVES GLUCOSE-HOMEOSTASIS; BARIATRIC SURGERY; TRANSPORTER SGLT2; PEPTIDE YY; SODIUM; DAPAGLIFLOZIN; MODULATION; ABSORPTION; INHIBITORS;
D O I
10.2337/db21-0768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bariatric surgery improves glucose homeostasis, but the underlying mechanisms are not fully elucidated. Here, we show that the expression of sodium-glucose cotransporter 2 (SGLT2/Slc5a2) is reduced in the kidney of lean and obese mice following vertical sleeve gastrectomy (VSG). Indicating an important contribution of altered cotransporter expression to the impact of surgery, inactivation of the SGLT2/Slc5a2 gene by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 attenuated the effects of VSG, with glucose excursions following intraperitoneal injection lowered by similar to 30% in wild-type mice but by similar to 20% in SGLT2-null animals. The effects of the SGLT2 inhibitor dapaglifozin were similarly blunted by surgery. Unexpectedly, effects of dapaglifozin were still observed in SGLT2-null mice, consistent with the existence of metabolically beneficial off-target effects of SGLT2 inhibitors. Thus, we describe a new mechanism involved in mediating the glucose-lowering effects of bariatric surgery.
引用
收藏
页码:1623 / 1635
页数:13
相关论文
共 50 条
  • [41] The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma
    Iwai, Shun
    Motono, Nozomu
    Oyama, Tsunehiro
    Shioya, Akihiro
    Yamada, Sohsuke
    Uramoto, Hidetaka
    ONCOLOGY, 2024, 102 (08) : 710 - 719
  • [42] TRANSCRIPTIONAL REGULATORY MECHANISMS OF SGLT2 GENE IN HUMAN KIDNEY
    Takesue, Hiroaki
    Hirota, Takeshi
    Tachimura, Mami
    Ieiri, Ichiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S61 - S61
  • [43] SGLT2 Inhibitors slow the Progression of chronic Kidney Disease
    不详
    DIABETOLOGE, 2019, 15 (06): : 567 - 567
  • [44] Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
    Kanda, Eiichiro
    Nangaku, Masaomi
    KIDNEY INTERNATIONAL, 2019, 96 (01) : 8 - 10
  • [45] Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
    DeFronzo, Ralph A.
    Reeves, W. Brian
    Awad, Alaa S.
    NATURE REVIEWS NEPHROLOGY, 2021, 17 (05) : 319 - 334
  • [47] Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease
    Makawi, Alaa T.
    Tawfik, Yahya M. K.
    Dixon, Dave L.
    McMahon, Gearoid M.
    Buckley, Leo F.
    AMERICAN JOURNAL OF NEPHROLOGY, 2024, 55 (04) : 417 - 420
  • [48] Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
    Ralph A. DeFronzo
    W. Brian Reeves
    Alaa S. Awad
    Nature Reviews Nephrology, 2021, 17 : 319 - 334
  • [49] A novel SLC5A2 heterozygous variant in a family with familial renal glucosuria
    Maho Hatano
    Tomohiro Udagawa
    Toru Kanamori
    Akito Sutani
    Takayasu Mori
    Eisei Sohara
    Shinichi Uchida
    Tomohiro Morio
    Masato Nishioka
    Human Genome Variation, 9
  • [50] Combination therapy with SGLT2 inhibitors for diabetic kidney disease
    Cai, Yuwen
    Liu, Xin
    Xu, Gaosi
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 127